Roflumilast (Daliresp) for Chronic Obstructive Pulmonary Disease

Underweight patients on roflumilast should be weighed regularly (about every four weeks) and treatment discontinued if clinically significant weight loss occurs.1,2,5 Blood levels of roflumilast may decrease when it is combined with strong cytochrome P450 (CYP450) inducers such as phenytoin (Dilanti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American family physician 2014-02, Vol.89 (4), p.300-301
Hauptverfasser:	Bazaldua, Oralia V., PharmD, BCPS, Davidson, Dewayne A., PharmD, Babb, Franklyn C., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Chronic obstructive pulmonary disease Drug dosages Insomnia Internal Medicine Mortality Patients Quality of life Suicides & suicide attempts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!